...
首页> 外文期刊>Arzneimittel-Forschung: =Drug Research >Pharmacokinetics and bioequivalence study of valacyclovir hydrochloride capsules after single dose administration in healthy Chinese male volunteers
【24h】

Pharmacokinetics and bioequivalence study of valacyclovir hydrochloride capsules after single dose administration in healthy Chinese male volunteers

机译:盐酸伐昔洛韦胶囊单剂量给药后在健康中国男性志愿者中的药代动力学和生物等效性研究

获取原文
获取原文并翻译 | 示例

摘要

The aim of the present study was to compare the bioavailability of valacyclovir (CAS 124832-26-4; INN: valaciclovir) from two valacyclovir hydrochloride (CAS 214832-27-5) capsules (150 mg/capsule as test preparation and 150 mg/capsule commercially available original capsule of the drug as reference preparation) in 20 Chinese healthy male volunteers, aged between 20 and 27. The study was conducted according to an open, randomized, single blind, 2-way crossover study design with a wash-out phase of 7 days. Blood samples for pharmaco-kinetic profiling were taken up to 24 h post-dose. Valacyclovir hydrochloride is rapidly converted to acyclovir (CAS 59277-89-3) after oral administration, so the pharmacokinetics and bioequivalence of valacyclovir hydrochloride can be studied by determining the plasma concentration of acyclovir. Plasma concentrations of acyclovir were determined with a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. The pharmacokinetic parameters of test and reference formulations were estimated as follows: the maximum plasma concentrations (C_(max) were 2.04 +- 0.43 mug/mL and 2.01 +- 0.50 mug/mL; the median T_(max) were 1.1 +- 0.3 h and 1.0 +- 0.3 h; plasma elimination half-lives (t_(1/2)) were 2.94 +- 0.42 h and 2.85 + 0.28 h. Values of AUC_(0-t) demonstrate nearly identical bioavailability of valacyclovir hydrochloride from the examined formulations. AUC_(0-15) were 6.70 +- 1.26 mug,h/ mL and 6.96 +- 1.25 mug,h/mL. Areas under the plasma concentration-time curve (AUC_(0-infinity)) were 6.90 +- 1.30 mug,h/mL and 7.15 + 1.31mug,h/mL. Both primary target parameters, AUC_(0-infinity) and AUC_(0-t) were tested parametrically by analysis of variance (ANOVA) and relative bioavailabil-ities were 96.69 +- 7.89 % for AUC_(0-infinity), 96.40 +- 8.0 % for AUC_(0-15). Bioequivalence between test and reference preparation was demonstrated for both parameters, AUC_(0-infinity) and AUC_(0-t). The 90% confidence intervals of the T/R-ratios of logarithmically transformed data were in the generally accepted range of 80-125 %. It meant that the test formulation was bioequivalent to the reference formulation for valacyclovir hydrochloride.
机译:本研究的目的是比较两种盐酸伐昔洛韦(CAS 214832-27-5)胶囊(试验制剂为150毫克/胶囊和150毫克/毫克)的伐昔洛韦(CAS 124832-26-4; INN:伐昔洛韦)的生物利用度。胶囊的市售药物原胶囊作为参考制剂)在20位年龄在20至27岁之间的20位中国健康男性志愿者中进行。该研究是根据开放,随机,单盲,2交叉研究的设计进行的,采用冲洗阶段为7天。在给药后24小时内采集用于药物动力学分析的血样。口服盐酸伐昔洛韦可迅速转化为阿昔洛韦(CAS 59277-89-3),因此可通过测定血浆中阿昔洛韦的浓度来研究盐酸伐昔洛韦的药代动力学和生物等效性。用验证的液相色谱-串联质谱法(LC-MS / MS)测定阿昔洛韦的血浆浓度。测试和参考制剂的药代动力学参数估算如下:最大血浆浓度(C_(max)为2.04±0.43杯/ mL和2.01±0.50杯/ mL;中值T_(max)为1.1 +-0.3 h和1.0±-0.3 h;血浆消除半衰期(t_(1/2))为2.94±-0.42 h和2.85 + 0.28 h。AUC_(0-t)的值表明盐酸伐昔洛韦的生物利用度几乎与AUC_(0-15)为6.70 +-1.26 mug,h / mL和6.96 +-1.25 cup,h / mL。血浆浓度-时间曲线下面积(AUC_(0-无穷大))为6.90 +- 1.30马克/小时/毫升和7.15 + 1.31马克/小时/毫升。通过方差分析(ANOVA)对两个主要目标参数AUC_(0-无穷大)和AUC_(0-t)进行了参数测试,相对生物利用度为AUC_(0-无穷大)为96.69 +-7.89%,AUC_(0-15)为96.40±-8.0%。测试和参考制剂之间的生物等效性均证明了AUC_(0-无穷大)和AUC_(0-t )。90%感到困惑对数转换数据的T / R比率的间隔在公认的80-125%范围内。这意味着测试制剂与盐酸伐昔洛韦的参考制剂生物等效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号